埃克替尼一线治疗基因敏感突变的晚期非小细胞肺癌的临床效果

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (606 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the short-term efficacy and adverse reactions of Icotinib as first-line therapy for advanced non-small cell lung cancer with sensitive gene mutations. Methods A retrospective analysis was conducted to the advanced non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations, who were treated in Affiliated Tumor Hospital of Guangxi Medical University from January 2013 to October 2015. The patients were prescribed Icotinib medication, once 125 mg, 3 times/day, until tumor showed progression or the toxic side effects could not be tolerated. The clinical efficacy, benefit ratio in different periods, and adverse reactions were evaluated. Results The median progression free survival (PFS) was 13.1 (2.1, 72.4) months in 59 patients, with completed remission (CR) in 2 cases, partial remission (PR) in 40 cases, stable disease (SD) in 13 cases, and progressive disease (PD) in 4 cases. The objective remission rate (CR+PR) was 71.2%, and the disease control rate (CR+PR+SD) was 93.2%. The main side effects were rash and diarrhea. No interstitial lung disease and hematologic toxicity were observed. Conclusion Icotinib can effectively improve the efficacy and benefit rate of advanced non-small cell lung cancer patients with EGFR mutations, with high safety, but the target and precise treatment of this drug still needs large sample and multicentric researches to be confirmed.

Key words： Icotinib Epidermal growth factor receptor Gene mutations Non-small cell lung cancer Short-term efficacy Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZENG Aiping YU Qitao

Cite this article:

ZENG Aiping YU Qitao. Clinical effect of Icotinib as first-line therapy for advanced non-small cell lung cancer with sensitive gene mutations[J]. 中国医药导报, 2017, 14(14): 80-83.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I14/80

[1] Siegel R，Ma J，Zou Z，et al. Cancer statistics，2014 [J]. CA Cancer J Clin，2014，64（1）：9-29.
[2] Chen WQ，Zeng HM，Zheng RS，et al. Cancer Incidence and Mortality in China，2007 [J]. Chin J Cancer Res，2012，24（1）：1-8.
[3] Novello S，Le Chevalier T. Chemotherapy for non-small cell lung cancer. Part 1：early stage disease [J]. Oncology，2003，17（3）：357-364.
[4] Macedo-Porez EO，Morales-Oyarvide V，Mendoza-Garcia VO，et al. Long progression-free survival with first-·line paclitaxel plus platinun is associated with impmved response and progression-free survival with second line docetaxel in advanced non-smal1 cell lung cancer [J]. Cancer Chemother Pharmacol，2014，74（4）：681-690.
[5] 王鑫，支修益.国际肺癌研究协会（IASLC）第八版肺癌TNM分期解读[J/CD].中华胸外科电子杂志，2016，3（3）：70-76.
[6] Huang H，Zhu S，Wang S，et al. Quick regression of brain metastases from lung adenocarcinoma with epidermal growth factor receptor-tyrosine kinase inhibitor treatment：A case report and literature review [J]. Mol Clin Oncol，2016，5（2）：380-382.
[7] Li JR，Zhang Y，Zheng JL. Icotinib combined whole brain radiotherapy for patients with brain metastasis from lung adenocarcinoma harboring epidermal growth factor receptor mutation [J]. J Thorac Dis，2016，8（7）：1504-1512.
[8] Jin Y，Shao Y，Shi X，et al. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing [J]. Oncotarget，2016，7（38）：61755-61763.
[9] Rao GE，Rahaman SA，Rani AP. Insights from molecular modeling，docking and simulation of imidazole nucleus containing chalcones with EGFR kinase domain for improved binding function [J]. Bioinformation，2016，12（2）：48-53.
[10] Mushi RT，Yang Y，Cai Q，et al. Ovarian metastasis from non-small cell lung cancer with ALK and EGFR mutations：A report of two cases [J]. Oncol Lett，2016，12（6）：4361-4366.
[11] Xu J，Shen L，Zhang BC，et al. HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib [J]. Oncol Lett，2016，12（6）：5363-5369.
[12] Biaoxue R，Hua L，Wenlong G，et al. Efficacy and safety of icotinib in treating non-small cell lung cancer：a systematic evaluation and meta-analysis based on 15 studies [J]. Oncotarget，2016，7（52）：86902-86913.
[13] Xu X，Zhao A，Zheng L，et al. PS01.65：EGFR Exon 19 Deletion Mutation Patients Obtain Optimal Survival in Icotinib Treated Non-Small Cell Lung Cancer Patient with Brain Metastases：Topic：Medical Oncology [J]. J Thorac Oncol，2016，11（11S）：S311.
[14] Zhu Z，Chai Y. Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib [J]. Thorac Cancer，2016，7（6）：681-683.
[15] Shi Y，Zhang L，Liu X，et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer（ICOGEN）：a randomised，double-blind phase 3 non-inferiority trial [J]. Lancet Oncol，2013，14（10）：953-961.
[16] Shi Y，Sun Y，Ding C，et al. China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment（2016 version）[J]. Zhongguo Fei Ai Za Zhi，2016，19（7）：489-494.
[17] Yao S，Zhi X，Wang R，et al. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations [J]. Thorac Cancer，2016，7（5）：543-548.
[18] 聂磊，李雅，邹春芳，等.盐酸埃克替尼治疗非小细胞肺癌疗效观察[J].癌症进展，2016，14（11）：1153-1155.
[19] Miyauchi E，Inoue A，Kobayashi K，et al. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase Ⅲ study comparing gefitinib with carboplatin plus paclitaxel（NEJ002）[J]. Jpn J Clin Oncol，2015，45（7）：670-676.
[20] Mitsudomi T，Morita S，Yatabe Y，et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405）：an open label，randomised phase 3 trial [J]. Lancet Oncol，2010，11（2）：121-128.
[21] Yang JJ，Zhou Q，Yan HH，et al. A phase Ⅲ randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations [J]. Br J Cancer，2017，116（5）：568-574.